NASDAQ · PETS
Healthcare · Medical - Pharmaceuticals
$1.24
Up+$0.04 (+3.33%)
Updated Nov 5, 2026, 4:08 AM
SID Score
2.9/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · PETS
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 4, 2026
PETS closed at $1.24 after 21 trading sessions, down 3.13% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | $1.21 | $1.25 | $1.21 | $1.24 | 49.55K |
| Nov 3, 2026 | $1.19 | $1.21 | $1.1801 | $1.20 | 39.58K |
| Nov 2, 2026 | $1.19 | $1.21 | $1.15 | $1.20 | 34.87K |
| Oct 30, 2026 | $1.171 | $1.20 | $1.17 | $1.19 | 42.35K |
| Oct 29, 2026 | $1.19 | $1.20 | $1.1672 | $1.18 | 12.51K |
| Oct 28, 2026 | $1.17 | $1.20 | $1.17 | $1.19 | 18.82K |
| Oct 27, 2026 | $1.17 | $1.22 | $1.161 | $1.18 | 62.03K |
| Oct 26, 2026 | $1.22 | $1.22 | $1.15 | $1.16 | 94.93K |
| Oct 23, 2026 | $1.17 | $1.2651 | $1.1699 | $1.22 | 272.24K |
| Oct 22, 2026 | $1.19 | $1.20 | $1.17 | $1.18 | 19.69K |
| Oct 21, 2026 | $1.21 | $1.21 | $1.18 | $1.19 | 62.71K |
| Oct 20, 2026 | $1.15 | $1.21 | $1.15 | $1.20 | 131.78K |
| Oct 19, 2026 | $1.16 | $1.20 | $1.15 | $1.15 | 95.95K |
| Oct 16, 2026 | $1.21 | $1.215 | $1.15 | $1.18 | 188.44K |
| Oct 15, 2026 | $1.21 | $1.23 | $1.20 | $1.22 | 49.96K |
| Oct 14, 2026 | $1.26 | $1.27 | $1.20 | $1.20 | 416.82K |
| Oct 13, 2026 | $1.27 | $1.30 | $1.27 | $1.27 | 88.99K |
| Oct 12, 2026 | $1.27 | $1.29 | $1.26 | $1.26 | 82.53K |
| Oct 9, 2026 | $1.28 | $1.2899 | $1.265 | $1.285 | 31.28K |
| Oct 8, 2026 | $1.28 | $1.29 | $1.265 | $1.28 | 143.29K |
| Oct 7, 2026 | $1.30 | $1.31 | $1.27 | $1.28 | 91.62K |
The latest Smart Investors Daily articles mentioning PETS.
Company
Market Activity
Research & News
PETS research
Company profile and research snapshot.
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 25, 2026 | Morgan Stanley | Underweight | — |
| Apr 17, 2025 | Morgan Stanley | Underweight | — |
| Aug 7, 2024 | Lake Street | Hold | — |
| Jun 12, 2024 | Lake Street | Buy | — |
| Jun 12, 2024 | Morgan Stanley | Underweight | — |
No generated briefing is available yet.
prnewswire.com · Dec 11, 2025
NEW YORK , Dec. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PetMed Express, Inc. ("PetMed" or the "Company") (NASDAQ: PETS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PETS.
